Is valproate pharmacotherapy associated with polycystic ovaries?

Annals of Pharmacotherapy

Volumn 33, Issue 11, 1999, Pages 1211-1216

  Chappell, Kimberly A ^a   Markowitz, John S ^b,c   Jackson, Cherry W ^d  

^a RUTGERS UNIVERSITY   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^d NONE

Author keywords

Anticonvulsant; Epilepsy; Polycystic ovarian syndrome; Valproate

Indexed keywords

ANTICONVULSIVE AGENT; VALPROIC ACID;

ANOVULATION; ARTICLE; DRUG EFFECT; DRUG RESPONSE; FEMALE; HUMAN; HYPERANDROGENISM; OVARY POLYCYSTIC DISEASE; PREVALENCE; PRIORITY JOURNAL; STEROID METABOLISM; SYNDROME; WEIGHT GAIN;

ANTICONVULSANTS; CLINICAL TRIALS; EPILEPSY; FEMALE; HUMANS; OVARIAN CYSTS; VALPROIC ACID;

EID: 0032743430     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.19096     Document Type: Article

References (44)

1. Package literature. Depakote (divalproex sodium). North Chicago, IL: Abbott Laboratories, 1999.
2. Top 200 drugs ranked by dispensed total prescriptions. Pharm Times 1998(April):42-9.
3. Phillips NI, Fowler LJ. The effects of sodium valproate on gamma-aminobutyrate metabolism and behaviour in naive and ethanolamine-O-sulphate pretreated rats and mice. Biochem Pharmacol 1982;31:2257-61.
4. Chapman A, Keane PE, Meldrum BS, Simiand J, Vernieres JC. Mechanism of anticonvulsant action of valproate. Prog Neurobiol 1982;19:315-59.
5. Rogawski MA, Porter RJ. Antiepileptic drugs: pharmacological mechanisms and clinical efficacy with consideration of promising developmental stage compounds. Pharmacol Rev 1990;42:279-92.
6. Emilien G, Maloteaux J-M. Pharmacological management of epilepsy. Mechanism of action, pharmacokinetic drug interactions, and new drug discovery possibilities. Int J Clin Pharmacol Ther 1998;36:181-94.
7. Franks S. Polycystic ovary syndrome. N Engl J Med 1995;333:853-61.
8. Taylor AE. Polycystic ovary syndrome. Endocrinol Metab Clin North Am 1998;27:877-903.
9. Legro RS, Driscoll D, Strauss JF, Fox J, Dunaif A. Evidence for a genetic basis for hyperandrogenemia in polycystic ovary syndrome. Proc Natl Acad Sci U S A 1998;95:14956-60.
10. Franks S, Gharani N, Waterworth D, Batty S, White D, Williamson R, et al. Genetics of polycystic ovary syndrome. Mol Cell Endocrinol 1998; 145:123-8.
11. Govind A, Obhrai MS, Clayton RN. Polycystic ovaries are inherited as an autosomal dominant trait: analysis of 29 polycystic ovary syndrome and 10 control families. J Clin Endocrinol Metab 1999;84:38-43.
12. Qin KN, Rosenfield RL. Role of cytochrome P450 c17 in polycystic ovary syndrome. Mol Cell Endocrinol 1998;145:111-21.
13. Yen SS. The polycystic ovary syndrome. Clin Endocrinol (Oxf) 1980; 12:177-207.
14. Isojärvi JIT, Laatikainen TJ, Knip M, Pakarinen AJ, Juntunen KTS, Myllylä VV. Obesity and endocrine disorders in women taking valproate for epilepsy. Ann Neurol 1996;39:579-84.
15. Herzog AG. Polycystic ovarian syndrome in women with epilepsy: epileptic or iatrogenic? Ann Neurol 1996;39:559-60.
16. Poison DW, Wadsworth J, Adams J, Franks S. Polycystic ovaries - a common finding in normal women. Lancet 1988;1:870-2.
17. Guzick D. Polycystic ovary syndrome: Symptomatology, pathophysiology, and epidemiology. Am J Obstet Gynecol 1998;179(suppl 6):S89-93.
18. Knochenhauer ES, Key TJ, Kahsarmiller M, Waggoner W, Boots LR, Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab 1998;83:3078-82.
19. Bilo L, Meo R, Valentino R, Buscaino GA, Striano S, Nappi C. Abnormal pattern of lutenizing hormone pulsatility in women with epilepsy. Fertil Steril 1991;55:705-11.
20. Wallace H, Shorvon S, Tallis R. Age-specific incidence and prevalence rates of treated epilepsy in an unselected population of 2,052,922 and age-specific fertility rates of women with epilepsy. Lancet 1998;352: 1970-3.
21. Perucca E. Clinical implications of hepatic microsomal enzyme induction by antiepileptic drugs. Pharmacol Ther 1987;33:139-44.
22. Isojärvi JIT, Pakarinen AJ, Ylipalosaari PJ, Myllylä VV. Serum hormones in male epileptic patients receiving anticonvulsant medication. Arch Neurol 1990;47:670-6.
23. Isojärvi JIT. Serum steroid hormones and pituitary function in female epileptic patients during carbamazepine therapy. Epilepsia 1990;31:438-45.
24. Kusunoki M, Yamamura T, Ichii S, Fujita S, Nakai T, Utsunomiya J. The effects of sodium valproate on plasma somatostatin and insulin in humans. J Clin Endocrinol Metab 1988;67:1060-3.
25. Morrell MJ. Maximizing the health of women with epilepsy: science and ethics in new drug development. Epilepsia 1997;38:S32-41.
26. Tephly TR, Burchell B. UDP-glucuronosyltransferases: a family of detoxifying enzymes. Trends Pharmacol Sci 1990;11:276-9.
27. Rittmaster RS. Androgen conjugates: physiology and clinical significance. Endocr Rev 1993;14:121-32.
28. Mackenzie PI, Owens IS, Burchell B, Bock KW, Bairoch A, Bélanger A, et al. The UDP-glycosyltransferase gene superfamily: recommended nomenclature update based on evolutionary divergence. Pharmacogenetics 1997;7:255-69.
29. Remmel RP. Metabolic isozymes: UDP-glucuronosyltransferases and other conjugate enzymes. In: Horri W, ed. Drug - drug interactions: analyzing in vitro - in vivo correlations. Washington, DC: IBC Inc., 1997: 1.2.1-1.2.34.
30. Samara EE, Granneman RG, Witt GF, Cavanaugh JH. Effect of valproate on the pharmacokinetics and pharmacodynamics of lorazepam. J Clin Pharmacol 1997;37:442-50.
31. Akula SK, Rege AB, Dreisbach AW, Dejace PM, Lertora JJ. Valproic acid increases cerebrospinal fluid zidovudine levels in a patient with AIDS. Am J Med Sci 1997;313:244-6.
32. Yuen AWC, Land G, Weatherley BC, Peck AW. Sodium valproate acutely inhibits lamotrigine metabolism. Br J Clin Pharmacol 1992;33: 511-3.
33. Sharp S, Mak LY, Smith DJ, Coughtrie MW. Inhibition of human and rabbit liver steroid and xenobiotic UDP-glucuronosyltransferases by tertiary amine drugs - implications for adverse drug reactions. Xenobiotica 1992;22:13-25.
34. Murialdo G, Galimberti CA, Gianelli MV, Rollero A, Polleri A, Copello F, et al. Effects of valproate, phenobarbital and carbamazepine on sex steroid setup in women with epilepsy. Clin Neuropharmacol 1998;21:52-8.
35. Breum L, Astrup A, Gram L, Andersen T, Stokholm KH, Christensen NJ, et al. Metabolic changes during treatment with valproate in humans: implication for untoward weight gain. Metabolism 1992;41:666-70.
36. Abeal JL, Agricola JC, Carreira JMP, Cabezas-Cerrato J. Influence of sodium valproate on late follicular phase pulsatile LH secretion in normal women. Clin Endocrinol (Oxf) 1991;35:477-83.
37. Abeal JL, Losada CR, Agricola JMC, Cabezas-Cerrato J. Influence of sodium valproate on medium - late luteal phase pulsatile LH secretion in normal women. Clin Endocrinol 1994;40:127-31.
38. Isojärvi JIT, Laatikainen TJ, Pakarinen AJ, Juntunen KT, Myllylä VV. Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy. N Engl J Med 1993;329:1383-8.
39. Isojärvi JIT, Rättyä J, Myllylä VV, Knip M, Koivunen R, Pakarinen AJ, et al. Valproate, lamotrigine, and insulin-mediated risks in women with epilepsy. Ann Neurol 1998;43:446-51.
40. Murialdo G, Galimberti CA, Magri F, Sampaolo P, Gianelli MV, Gazzerro E, et al. Menstrual cycle and ovary alterations in women on anti-epileptic therapy. J Endocrinol Invest 1997;20:519-26.
41. Vainionpää LK, Rättyä J, Knip M, Tapanainen JS, Pakarinen AJ, Lanning P, et al. Valproate-induced hyperandrogenism during pubertal maturation in girls with epilepsy. Ann Neurol 1999;45:444-50.
42. Johnston HF. More on valproate and polycystic ovaries (letter). J Am Acad Child Adolesc Psychiatry 1999;38:354.
43. Corman CL, Leung NM, Guberman AH. Weight gain in epileptic patients during treatment with valproic acid - a retrospective study. Can J Neurol Sci 1997;24:240-4.
44. Eberle AJ. Valproate and polycystic ovaries (letter). J Am Acad Child Adolesc Psychiatry 1998;37:1009.